• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Regulation of cell migration and chemokine expressions on cytotoxic T cells induced by percutaneous immunization in melanoma patients

Research Project

Project/Area Number 19591301
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Dermatology
Research InstitutionHamamatsu University School of Medicine

Principal Investigator

YAGI Hiroaki  Hamamatsu University School of Medicine, 医学部・附属病院, 講師 (20242779)

Co-Investigator(Kenkyū-buntansha) SEO Naohiro  浜松医科大学, 医学部, 助教 (50283354)
Co-Investigator(Renkei-kenkyūsha) SEO Naohiro  浜松医科大学, 医学部, 助教 (50283354)
Project Period (FY) 2007 – 2008
Project Status Completed (Fiscal Year 2008)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2008: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2007: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords悪性黒色腫 / メラノーマ / 免疫療法 / 細胞障害性T細胞 / ケモカインン受容体 / ケモカイン受容体 / 細胞走化 / ケモタキシス / ペプチド / ケモカイン / 樹状細胞 / 経皮ペプチド免疫療法 / ランゲルハウス細胞
Research Abstract

倫理委員会承認のもとに、悪性黒色腫に対する特異ペプチドを用いて経皮的に免疫を行う経皮免疫療法(PPI)を病期III以上の患者に施行した。PPIにより患者末梢血にペプチドを抗原特異的に認識する腫瘍細胞特異的な細胞障害活性を有する細胞障害性T細胞(CTL)の誘導に成功した。このCTLの細胞表面に発現されるT細胞受容体Vbを解析したところ、複数の患者で少数のVbに偏りがみられた。これらのVbを有するCTLのケモカイン受容体発現を調べたところ、多くはCXCR3陽性、CCR4陰性であることがわかった。そこで、CCDカメラでreal-timeに細胞の動きが観察できるTAXIScanという装置を用いて細胞走化の解析を行った。

Report

(3 results)
  • 2008 Annual Research Report   Final Research Report ( PDF )
  • 2007 Annual Research Report
  • Research Products

    (7 results)

All 2008 2007

All Journal Article (4 results) (of which Peer Reviewed: 2 results) Presentation (3 results)

  • [Journal Article] Promiscuous interaction between gold-specific T cells and APCs in gold allergy.2008

    • Author(s)
      Hashizume H, Seo N, Ito T, Takigawa M, Yagi H.
    • Journal Title

      J Immunol 181(11)

      Pages: 8096-102

    • Related Report
      2008 Final Research Report
  • [Journal Article] Palpable archiform migratory erythema preceded by B-cell pseudolymphoma in a Japaneseman2008

    • Author(s)
      Yagi H, Ito T, Ito N, Horibe T, Yoshinari Y, Takigawa M, Hashizume H.
    • Journal Title

      Acta Derm Venereol 88

      Pages: 171-172

    • Related Report
      2007 Annual Research Report
    • Peer Reviewed
  • [Journal Article] The current status and future direction of percutaneous peptide immunization against melanoma.2007

    • Author(s)
      Seo N, Takigawa M
    • Journal Title

      J Dermatol Sci 48(2)

      Pages: 77-85

    • NAID

      10024117410

    • Related Report
      2008 Final Research Report
  • [Journal Article] Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma with a CD15(+)CD30(-)phenotype2007

    • Author(s)
      Yoshizawa N, Yagi H, Horibe T, Takigawa M, Sugiura M.
    • Journal Title

      Eur J Dermatol 17

      Pages: 441-2

    • Related Report
      2007 Annual Research Report
    • Peer Reviewed
  • [Presentation] Long-term immunological and clinical outcomes in advanced melanoma patients treated with percutaneous peptide immunization2008

    • Author(s)
      Yagi H
    • Organizer
      the 10th International Symposium on Dendritic Cells
    • Place of Presentation
      Kobe
    • Related Report
      2008 Final Research Report
  • [Presentation] Long-term immunological and clinical outcomes in advanced melanoma patients treated with percutaneous peptide immunization2008

    • Author(s)
      八木宏明
    • Organizer
      the 10th International Symposium on Dendritic Cells
    • Place of Presentation
      神戸
    • Related Report
      2008 Annual Research Report
  • [Presentation] 日本の皮膚リンパ腫とメラノーマ特異性と新たな治療戦略皮膚リンパ腫、メラノーマのExperimental therapy2007

    • Author(s)
      八木 宏明
    • Organizer
      日本癌治療学会
    • Place of Presentation
      京都
    • Year and Date
      2007-10-24
    • Related Report
      2007 Annual Research Report

URL: 

Published: 2007-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi